<DOC>
	<DOCNO>NCT02429869</DOCNO>
	<brief_summary>Zortress ( everolimus ) , 40-O- ( 2-hydroxyethyl ) -derivative rapamycin , mTOR inhibitor approve rejection prophylaxis kidney transplant recipient . mTOR inhibition may favorably impact HIV viral reservoir , hypothesize add everolimus transplant immunosuppressive regimen HIV positive transplant recipient decrease HIV persistence CD4+ lymphocytes .</brief_summary>
	<brief_title>Impact Everolimus HIV Persistence Post Kidney Liver Transplant</brief_title>
	<detailed_description>Open-label , single arm study enroll antiretroviral-treated HIV-infected adult well post-liver post-kidney transplant eligible willing add everolimus immunosuppressive regimen ( target trough level 3-8 ng/ml ) . Calcineurin inhibitor decrease obtain 50 % reduction trough level addition everolimus . Subjects maintain regimen 6 month . Biologic specimens intensive immunology virology study obtain , exposure everolimus . Samples analyze screening , baseline ( prior addition everolimus ) , week 8 26 ( everolimus ) , week 52 ( 6 month post everolimus discontinuation ) .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Solid organ ( kidney , kidney/pancreas , liver ) transplant recipient 2 . Male female ≥ 18 year age . 3 . Documentation HIV1 infection diagnosis evidence licensed ELISA confirmation Western Blot , document history detectable HIV1 RNA ) 4 . HIV1 plasma RNA &lt; 50 copies/ml least 2 year least one measurement per year recent viral load within 16 week enrollment study drug initiation . Episodes single HIV plasma RNA 50 500 copies/ml exclude participation subsequent HIV plasma RNA &lt; 50 copies/ml . 5 . CD4+ T cell count great 200 cell/µl within 16 week enrollment study drug initiation . 6 . Receiving combination antiretroviral therapy ( least 3 agent ) 7 . Written inform consent obtain subject subject 's legal representative ability subject comply requirement study . 1 . Pregnant , breastfeeding , unwilling practice birth control participation study . 2 . Presence condition abnormality opinion Investigator would compromise safety patient quality data . 3 . Patients intend modify antiretroviral therapy next 6 month reason . 4 . Serious illness require hospitalization parenteral antibiotic within precede 3 month . 5 . A screen hemoglobin 11.5 g/dL . 6 . A screening TSH consistent hypothyroidism . 7 . Significant renal disease ( eGFR &lt; 60 ml/min ) acute nephritis 8 . Clinically active hepatitis evidence clinical jaundice Grade 2 high liver function test abnormality . 9 . Hepatic cirrhosis decompensated chronic liver disease . 10 . Concurrent treatment immunomodulatory drug , interferonalpha , exposure immunomodulatory drug past 16 week ( outside standard immunosuppression ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>